摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(p-toluenesulfonyloxy)-2-cyclopenten-1-one | 205999-79-7

中文名称
——
中文别名
——
英文名称
3-(p-toluenesulfonyloxy)-2-cyclopenten-1-one
英文别名
3-oxocyclopent-1-en-1-yl 4-methylbenzenesulfonate;(3-Oxocyclopenten-1-yl) 4-methylbenzenesulfonate;(3-oxocyclopenten-1-yl) 4-methylbenzenesulfonate
3-(p-toluenesulfonyloxy)-2-cyclopenten-1-one化学式
CAS
205999-79-7
化学式
C12H12O4S
mdl
——
分子量
252.291
InChiKey
DUNMIVQLQNMUET-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    415.2±45.0 °C(Predicted)
  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    68.8
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] TARGETED COVALENT PROBES AND INHIBITORS OF PROTEINS CONTAINING REDOX-SENSITIVE CYSTEINES
    [FR] SONDES COVALENTES CIBLÉES ET INHIBITEURS DE PROTÉINES CONTENANT DES CYSTÉINES SENSIBLES À L'OXYDORÉDUCTION
    摘要:
    揭示了用于修饰治疗重要蛋白质(特别是激酶和磷酸酶)的亚硫酰形式(即亚硫酸,RSOH和亚硫酰胺,RSNR'2)的共价、不可逆的小分子抑制剂,其中组合物包括具有取代芳基或杂环核结构的化合物,促进与特定蛋白质的结合相互作用,以及能够与蛋白质中的亚硫酸或亚硫酰胺修饰的半胱氨酸残基形成共价键的亲核反应中心(碳、氮、硫或磷)。还揭示了合成这些化合物的方法,以及使用它们确定包含活性化合物的化学组合物对特定蛋白质的生物活性以及确定抑制剂对特定蛋白质的效力的方法。
    公开号:
    WO2014089546A1
  • 作为产物:
    描述:
    1,3-环戊二酮对甲苯磺酰氯三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 0.17h, 以88%的产率得到3-(p-toluenesulfonyloxy)-2-cyclopenten-1-one
    参考文献:
    名称:
    二级烷基铜试剂与 3-卤代不饱和羰基衍生物的非对映和对映选择性交叉偶联。
    摘要:
    手性仲烷基铜试剂由相应的烷基碘化物制备,并通过使用t BuLi(-100 °C,1 分钟)进行 I/Li 交换,然后与 CuBr ⋅ P(OEt) 3 (-100 ° C,20 秒)。这些立体定义的仲烷基铜与几种 3-碘或 3-溴不饱和羰基衍生物进行立体保持交叉偶联,从而以良好的收率和高非对映选择性(dr 高达 96:4)生成相应的 γ-甲基化迈克尔受体。该方法扩展到对映异构体富集的烷基铜,提供具有高达 90% ee的光学富集的高级天然产物中间体。
    DOI:
    10.1002/chem.202002297
点击查看最新优质反应信息

文献信息

  • Synthesis of β-triazolylenones via metal-free desulfonylative alkylation of <i>N</i>-tosyl-1,2,3-triazoles
    作者:Soumyaranjan Pati、Renata G Almeida、Eufrânio N da Silva Júnior、Irishi N N Namboothiri
    DOI:10.3762/bjoc.17.66
    日期:——
    N-tosyl-1,2,3-triazoles under metal-free conditions leading to β-triazolylenones is reported here. The present study encompasses the synthesis of triazoles with a new substitution pattern in a single step from cyclic 1,3-dicarbonyl compounds and N-tosyl triazole in moderate to high yields. Our synthesis takes place with complete regioselectivity as confirmed by crystallographic analysis which is rationalized
    在此报道了N-甲苯磺酰基-1,2,3-三唑在无属条件下的脱磺酰基烷基化反应,生成β-三唑烯酮。本研究涵盖了从环状1,3-二羰基化合物和N-甲苯磺酰基三唑以中等至高收率一步合成具有新取代模式的三唑。如晶体学分析所证实的那样,我们的合成具有完全的区域选择性,该晶体学分析通过适当的机械方案被合理化。该方法为合成新的功能化1,2,3-三唑提供了有效,通用和直接的策略。
  • Rhodium-Catalyzed Asymmetric 1,6-Addition of Aryltitanates to Enynones Giving Axially Chiral Allenes
    作者:Tamio Hayashi、Norihito Tokunaga、Kazuya Inoue
    DOI:10.1021/ol036309f
    日期:2004.1.1
    [GRAPHICS]The addition of aryltitanate reagents ArTi(OPr-i)(4)Li to 3-alkynyl-2-en-1-ones in the presence of chlorotrimethylsilane and a rhodium-(R)-segphos as a catalyst proceeded in a 1,6-fashion to give a high yield of axially chiral allenylalkenyl silyl enol ethers with up to 93% ee.
  • Investigation of the N-Substituent Conformation Governing Potency and μ Receptor Subtype-Selectivity in (+)-(3<i>R</i>,4<i>R</i>)-Dimethyl-4-(3-hydroxyphenyl)- piperidine Opioid Antagonists
    作者:James B. Thomas、S. Wayne Mascarella、Richard B. Rothman、John S. Partilla、Heng Xu、Karen B. McCullough、Christina M. Dersch、Buddy E. Cantrell、Dennis M. Zimmerman、F. Ivy Carroll
    DOI:10.1021/jm980063g
    日期:1998.5.1
    A study of the binding site requirements associated with the N-substituent of (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (4) derivatives was undertaken using a set of rigid vs flexible N-substituents. The study showed that compounds 7-9 bearing the trans-cinnamyl N-substituent most closely reproduced the potency at the opioid receptor of the flexible N-propylphenyl or N-propylcyclohexyl analogues previously reported. Neither the N-substituted cis-cinnamyl nor the cis-phenylcyclopropylmethyl compounds 10 and 11, respectively, showed high affinity for the opioid receptor. However, the N-trans-phenylcyclopropylmethyl compound 12 closely approximated the affinity of compounds 7-9. Additionally, we found that free rotation of the phenyl ring is necessary for high affinity binding and mu receptor subtype selectivity as the planar N-substituted thianaphthylmethyl and benzofuranylmethyl compounds 13 and 14 had significantly lower binding affinities. Altogether, these findings suggest that the high binding affinity, selectivity, and antagonist potency of N-propylphenyl or N-propylcyclohexyl analogues of (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) (4) are achieved via a conformation wherein the connecting chain of the N-substituents is extended away from piperidine nitrogen with the appended ring system rotated out-of-plane relative to the connecting chain atoms. This conformation is quite similar to that observed in the solid state for 5, as determined by single crystal X-ray analysis. Additionally, it was found that, unlike naltrexone, N-substituents bearing secondary carbons attached directly to the piperidine nitrogen of 4 suffer dramatic losses of potency vs analogues not substituted in this manner. Using a functional assay which measured stimulation or inhibition of [S-35]GTP-gamma-S binding, we show that the trans-cinnamyl analogues of (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (4) retain opioid pure antagonist activity and possess picomolar antagonist potency at the mu receptor.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫